Bolus followed by continuous infusion interleukin-2 in patients with metastatic malignant melanoma and kidney cancer previously treated with interleukin-2.
Six patients with either melanoma (3) or kidney cancer (3) who had experienced disease progression on outpatient interleukin-2 regimens were subsequently treated with inpatient bolus Interleukin-2 (IL-2) 36 MIU/m(2) followed by continuous infusion IL-2 18 MIU/m(2)/day for 3 days. Cycles were repeated every 2 weeks up to four times, then every 3-4 weeks if tolerated and in the absence of disease progression. Two patients (one each with kidney cancer and melanoma) have achieved partial responses. One patient with kidney cancer and hepatic metastases has had a minor response. Interleukin-2 given at this dose and schedule shows some evidence of activity in patients who have received prior outpatient IL-2.
D000328:Adult; D000368:Aged; D024221:Antineoplastic Protocols; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D015996:Survival Rate; D016896:Treatment Outcome
D007376:Interleukin-2